Larsen Stephen R, Chng Keefe, Battah Fiona, Martiniello-Wilks Rosetta, Rasko John E J
Centenary Institute, University of Sydney, Sydney, New South Wales, Australia.
Stem Cells. 2008 Nov;26(11):2974-80. doi: 10.1634/stemcells.2008-0560. Epub 2008 Aug 21.
Peripheral blood stem cells (PBSCs), usually mobilized with granulocyte colony-stimulating factor (G-CSF) alone or in combination with chemotherapy, are the preferred source of cells for hemopoietic stem cell transplantation. Up to 25% of otherwise eligible transplant recipients fail to harvest adequate PBSCs. Therefore it is important to investigate existing and novel reagents to improve PBSC mobilization. Because of marked interindividual variation in humans, we developed a robust nonhuman primate model that allows the direct comparison of the efficacy of two PBSC mobilization regimens within the same animal. Using this model, we compared pegylated G-CSF (pegG-CSF) with standard G-CSF and compared the combination of G-CSF and pegylated megakaryocyte growth and development factor (pegMGDF) with G-CSF plus stem cell factor (SCF) by measuring the levels of CD34(+) cells, colony-forming cells (CFCs), and SCID repopulating cells (SRCs) before and after cytokine administration. Mobilization of CD34(+) cells, CFCs and SRCs using pegG-CSF achieved similar levels to those resulting from 5 days of standard G-CSF. The combination of G-CSF+pegMGDF mobilized progenitors to levels similar to G-CSF+SCF but greater than standard G-CSF for CD34(+) cells and CFC. This first direct comparison of PBSC mobilization in individual primates demonstrates that peg-G-CSF is equivalent to daily G-CSF and that the addition of pegMGDF to G-CSF improves mobilization. In light of the development of new thrombopoietin agonists, these data offer the potential for improved stem cell mobilization strategies. Disclosure of potential conflicts of interest is found at the end of this article.
外周血干细胞(PBSCs)通常单独使用粒细胞集落刺激因子(G-CSF)或与化疗联合动员,是造血干细胞移植的首选细胞来源。高达25%原本符合条件的移植受者未能采集到足够的PBSCs。因此,研究现有的和新型试剂以改善PBSC动员很重要。由于人类个体间存在显著差异,我们建立了一个强大的非人类灵长类动物模型,该模型允许在同一只动物体内直接比较两种PBSC动员方案的疗效。使用该模型,我们通过测量细胞因子给药前后CD34(+)细胞、集落形成细胞(CFCs)和重症联合免疫缺陷(SCID)重建细胞(SRCs)的水平,将聚乙二醇化G-CSF(pegG-CSF)与标准G-CSF进行比较,并将G-CSF与聚乙二醇化巨核细胞生长和发育因子(pegMGDF)的组合与G-CSF加干细胞因子(SCF)进行比较。使用pegG-CSF动员CD34(+)细胞、CFCs和SRCs达到的水平与标准G-CSF使用5天所产生的水平相似。G-CSF + pegMGDF组合动员祖细胞的水平与G-CSF + SCF相似,但对于CD34(+)细胞和CFCs而言,高于标准G-CSF。在个体灵长类动物中对PBSC动员进行的首次直接比较表明,聚乙二醇化G-CSF等同于每日使用的G-CSF,并且在G-CSF中添加pegMGDF可改善动员效果。鉴于新型血小板生成素激动剂的发展,这些数据为改进干细胞动员策略提供了潜力。潜在利益冲突的披露见本文末尾。